New Frontiers Meeting

The 2027 ECNP New Frontiers Meeting will focus on one of the most consequential questions in mental health today: what can artificial intelligence realistically deliver for patients, clinicians and health systems and where are its limits?

While AI is advancing rapidly across psychiatry and neuroscience, the translation into routine clinical care remains uncertain. Promising developments in areas such as AI-supported clinical interviews, digital phenotyping, and data-driven biomarkers are raising expectations for earlier diagnosis, better stratification of patients, and more personalised treatment. At the same time, robust evidence of clinical impact is still emerging, and key challenges around validation, interpretability, and implementation remain unresolved.

This meeting will bring together leading researchers, clinicians, industry partners, regulators, and people with lived experience to critically examine where AI adds genuine value in mental health care. Particular attention will be given to diagnostic and treatment support tools, the development and clinical utility of AI-derived biomarkers, and how these approaches might be integrated into real-world psychiatric practice.

Importantly, the programme will also address the risks and limitations of AI in mental health, including bias, over-reliance on automated systems, data governance, and patient safety. The aim is not to promote technology for its own sake, but to assess what is clinically meaningful, what is not yet ready, and what evidence is still needed.

In line with the ECNP New Frontiers format, the meeting provides a neutral, precompetitive space for open discussion across disciplines, with a clear focus on translation into better outcomes for patients.